# SNV1521

Source: https://onco.cc/drugs/snv1521/  
OnCo record `snv1521` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SNV1521 is an experimental pill being studied to block a DNA-repair enzyme in cancer cells.

## Summary

Synnovation describes SNV1521 as a PARP1-selective inhibitor. The linked registry records distinguish recruiting, closed, and discontinued studies; those states do not establish comparative efficacy or approval.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-10-06
- Modality: Small-molecule PARP1 inhibitor
- Mechanism: Synnovation describes SNV1521 as a PARP1-selective inhibitor.

## Sources

- ClinicalTrials.gov NCT07756281: https://clinicaltrials.gov/study/NCT07756281
- ClinicalTrials.gov NCT06220864: https://clinicaltrials.gov/study/NCT06220864
- Primary publication or sponsor source: https://www.synnovationtx.com/news/parp1-fip-pressrelease

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- targets: [PARP](https://onco.cc/targets/parp/)
- trials: [First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer](https://onco.cc/trials/nct07756281/), [SNV1521 in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct06220864/)

---
JSON: https://onco.cc/api/v1/entities/snv1521.json